

**1 Structurally diverse triterpenes obtained
2 from the fruits of *Ziziphus jujuba* Mill. as
3 inflammation inhibitors by NF-κB signaling
4 pathway**

5

6 **Jingya Ruan¹, Fan Sun¹, Mimi Hao², Lifeng Han¹, Haiyang Yu², Fanyou Lin³,**
7 **Lijuan Wang³, Guohao Cao², Yi Zhang^{1,2,*} and Tao Wang^{1,2,*}**

8

9 **Affiliations:**

10 ^a *Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of
11 Traditional Chinese Medicine, 312 Anshanxi Road, Nankai District, Tianjin, 300193,
12 China*

13 ^b *Tianjin Key Laboratory of TCM Chemistry and Analysis, Institute of Traditional
14 Chinese Medicine, Tianjin University of Traditional Chinese Medicine, 312 Anshanxi
15 Road, Nankai District, Tianjin, 300193, China*

16 ^c *Xiangyu Group Inc., 30 Xiangyu Road, Economic and Technological Development
17 District, 276023, Linyi city, Shandong, China*

18


19 *Corresponding author. Tel./Fax: +86 22 5959 6163. E-mail:

20 zhwwxzh@tjutcm.edu.cn (Y. Zhang); wangtao@tjutcm.edu.cn (T. Wang).

22	Chart S1. The extraction and isolation progress of triterpenes 1–29 from <i>Z. jujuba</i>	5
23	S1. The ^1H and ^{13}C NMR data of compounds 1–29	6
24	Fig. S1. ^1H NMR (600MHz, CD_3OD) spectrum of compound 1	16
25	Fig. S2. ^{13}C NMR (150MHz, CD_3OD) spectrum of compound 1	16
26	Fig. S3. The ^1H ^1H COSY (CD_3OD) spectrum of compound 1	17
27	Fig. S4. The HSQC (CD_3OD) spectrum of compound 1	17
28	Fig. S5. The HMBC (CD_3OD) spectrum of compound 1	18
29	Fig. S6. The NOESY (CD_3OD) spectrum of compound 1	18
30	Fig. S7. The ESI-Q-Orbitrap MS spectrum of compound 1	19
31	Fig. S8. ^1H NMR (600MHz, CDCl_3) spectrum of compound 2	20
32	Fig. S9. ^{13}C NMR (150MHz, CDCl_3) spectrum of compound 2	20
33	Fig. S10. The ESI-Q-Orbitrap MS spectrum of compound 2	21
34	Fig. S11. ^1H NMR (600MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 3	22
35	Fig. S12. ^{13}C NMR (150MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 3	22
36	Fig. S13. The ESI-Q-Orbitrap MS spectrum of compound 3	23
37	Fig. S14. ^1H NMR (500MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 4	24
38	Fig. S15. ^{13}C NMR (125MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 4	24
39	Fig. S16. The ESI-Q-Orbitrap MS spectrum of compound 4	25
40	Fig. S17. ^1H NMR (500MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 5	26
41	Fig. S18. ^{13}C NMR (125MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 5	26
42	Fig. S19. The ESI-Q-Orbitrap MS spectrum of compound 5	27
43	Fig. S20. ^1H NMR (500MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 6	28
44	Fig. S21. ^{13}C NMR (125MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 6	28
45	Fig. S22. The ESI-Q-Orbitrap MS spectrum of compound 6	29
46	Fig. S23. ^1H NMR (600MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 7	30
47	Fig. S24. ^{13}C NMR (150MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 7	30
48	Fig. S25. The ESI-Q-Orbitrap MS spectrum of compound 7	31
49	Fig. S26. ^1H NMR (600MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 8	32
50	Fig. S27. ^{13}C NMR (150MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 8	32
51	Fig. S28. The ESI-Q-Orbitrap MS spectrum of compound 8	33
52	Fig. S29. ^1H NMR (600MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 9	34
53	Fig. S30. ^{13}C NMR (150MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 9	34
54	Fig. S31. The ESI-Q-Orbitrap MS spectrum of compound 9	35
55	Fig. S32. ^1H NMR (600MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 10	36
56	Fig. S33. ^{13}C NMR (150MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum-1 of compound 10	36
57	Fig. S34. ^{13}C NMR (150MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum-2 of compound 10	37
58	Fig. S35. The ESI-Q-Orbitrap MS spectrum of compound 10	37
59	Fig. S36. ^1H NMR (500MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 11	38
60	Fig. S37. ^{13}C NMR (125MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 11	38
61	Fig. S38. The ESI-Q-Orbitrap MS spectrum of compound 11	39
62	Fig. S39. ^1H NMR (600MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 12	40
63	Fig. S40. ^{13}C NMR (150MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum-1 of compound 12	40
64	Fig. S41. ^{13}C NMR (150MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum-2 of compound 12	41
65	Fig. S42. The ESI-Q-Orbitrap MS spectrum of compound 12	41

66	Fig. S43. ^1H NMR (500MHz, C ₅ D ₅ N) spectrum of compound 13	42
67	Fig. S44. ^{13}C NMR (125MHz, C ₅ D ₅ N) spectrum of compound 13	42
68	Fig. S45. The ESI-Q-Orbitrap MS spectrum of compound 13	43
69	Fig. S46. ^1H NMR (600MHz, CD ₃ OD) spectrum of compound 14	44
70	Fig. S47. ^{13}C NMR (150MHz, CD ₃ OD) spectrum of compound 14	44
71	Fig. S48. The ESI-Q-Orbitrap MS spectrum of compound 14	45
72	Fig. S49. ^1H NMR (600MHz, DMSO- <i>d</i> ₆) spectrum of compound 15	46
73	Fig. S50. ^{13}C NMR (150MHz, DMSO- <i>d</i> ₆) spectrum of compound 15	46
74	Fig. S51. The ESI-Q-Orbitrap MS spectrum of compound 15	47
75	Fig. S52. ^1H NMR (600MHz, DMSO- <i>d</i> ₆) spectrum of compound 16	48
76	Fig. S53. ^{13}C NMR (150MHz, DMSO- <i>d</i> ₆) spectrum of compound 16	48
77	Fig. S54. The ESI-Q-Orbitrap MS spectrum of compound 16	49
78	Fig. S55. ^1H NMR (600MHz, C ₅ D ₅ N) spectrum of compound 17	50
79	Fig. S56. ^{13}C NMR (150MHz, C ₅ D ₅ N) spectrum of compound 17	50
80	Fig. S57. The ESI-Q-Orbitrap MS spectrum of compound 17	51
81	Fig. S58. ^1H NMR (600MHz, C ₅ D ₅ N) spectrum of compound 18	52
82	Fig. S59. ^{13}C NMR (150MHz, C ₅ D ₅ N) spectrum-1 of compound 18	52
83	Fig. S60. ^{13}C NMR (150MHz, C ₅ D ₅ N) spectrum-2 of compound 18	53
84	Fig. S61. The ESI-Q-Orbitrap MS spectrum of compound 18	53
85	Fig. S62. ^1H NMR (600MHz, C ₅ D ₅ N) spectrum of compound 19	54
86	Fig. S63. ^{13}C NMR (150MHz, C ₅ D ₅ N) spectrum of compound 19	54
87	Fig. S64. The ESI-Q-Orbitrap MS spectrum of compound 19	55
88	Fig. S65. ^1H NMR (600MHz, C ₅ D ₅ N) spectrum of compound 20	56
89	Fig. S66. ^{13}C NMR (150MHz, C ₅ D ₅ N) spectrum of compound 20	56
90	Fig. S67. The ESI-Q-Orbitrap MS spectrum of compound 20	57
91	Fig. S68. ^1H NMR (500MHz, C ₅ D ₅ N) spectrum of compound 21	58
92	Fig. S69. ^{13}C NMR (125MHz, C ₅ D ₅ N) spectrum of compound 21	58
93	Fig. S70. The ESI-Q-Orbitrap MS spectrum of compound 21	59
94	Fig. S71. ^1H NMR (500MHz, C ₅ D ₅ N) spectrum of compound 22	60
95	Fig. S72. ^{13}C NMR (125MHz, C ₅ D ₅ N) spectrum of compound 22	60
96	Fig. S73. The ESI-Q-Orbitrap MS spectrum of compound 22	61
97	Fig. S74. ^1H NMR (600MHz, C ₅ D ₅ N) spectrum of compound 23	62
98	Fig. S75. ^{13}C NMR (150MHz, C ₅ D ₅ N) spectrum-1 of compound 23	62
99	Fig. S76. ^{13}C NMR (150MHz, C ₅ D ₅ N) spectrum-2 of compound 23	63
100	Fig. S77. The ESI-Q-Orbitrap MS spectrum of compound 23	63
101	Fig. S78. ^1H NMR (600MHz, C ₅ D ₅ N) spectrum of compound 24	64
102	Fig. S79. ^{13}C NMR (150MHz, C ₅ D ₅ N) spectrum-1 of compound 24	64
103	Fig. S80. The ESI-Q-Orbitrap MS spectrum of compound 24	65
104	Fig. S81. ^1H NMR (600MHz, C ₅ D ₅ N) spectrum of compound 25	66
105	Fig. S82. ^{13}C NMR (150MHz, C ₅ D ₅ N) spectrum of compound 25	66
106	Fig. S83. The ESI-Q-Orbitrap MS spectrum of compound 25	67
107	Fig. S84. ^1H NMR (600MHz, C ₅ D ₅ N) spectrum of compound 26	68
108	Fig. S85. ^{13}C NMR (150MHz, C ₅ D ₅ N) spectrum-1 of compound 26	68
109	Fig. S86. ^{13}C NMR (150MHz, C ₅ D ₅ N) spectrum-2 of compound 26	69

110	Fig. S87. The ESI-Q-Orbitrap MS spectrum of compound 26	69
111	Fig. S88. ^1H NMR (500MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 27	70
112	Fig. S89. ^{13}C NMR (125MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 27	70
113	Fig. S90. The ESI-Q-Orbitrap MS spectrum of compound 27	71
114	Fig. S91. ^1H NMR (500MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 28	72
115	Fig. S92. ^{13}C NMR (125MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 28	72
116	Fig. S93. The ESI-Q-Orbitrap MS spectrum of compound 28	73
117	Fig. S94. ^1H NMR (600MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 29	74
118	Fig. S95. ^{13}C NMR (150MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum-1 of compound 29	74
119	Fig. S96. ^{13}C NMR (150MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum-2 of compound 29	75
120	Fig. S97. The ESI-Q-Orbitrap MS spectrum of compound 29	75
121	Fig. S98. The MTT assay compounds 1–29 at 1, 5, 10, 25 and 50 μM	76
122	Fig. S99. The raw data of Fig. 3.....	77
123	Tab. S1. ^{13}C -NMR data for 2–11	78
124	Tab. S2. ^{13}C -NMR data for 12–20	79
125	Tab. S3. ^{13}C -NMR data for 21–29	80
126	Tab. S4. Comparison ^1H and ^{13}C NMR chemical shifts of maslinic acid, augustinic acid, bredemolic acid and 3- <i>epi</i> -maslinic acid.....	81



132 **S1. The NMR data of compounds 2–29**

133

134 *Lup-20 (29)-en-3-on-28-oic acid (2, purity percentage is 98.3%)*: White powder;
135 ^1H NMR (CDCl_3 , 500 MHz) spectroscopic data: δ 0.92, 0.99, 0.99, 1.02, 1.07, 1.70
136 (3H each, all s, H₃-26, 25, 27, 24, 23 and 29), 4.61, 4.75 (1H each, both br. s, H₂-30);
137 ^{13}C NMR (CDCl_3 , 125 MHz) spectroscopic data: see Tab. S1; ESI-Q-Orbitrap MS
138 *m/z* 453.33734 [M–H][–] (calcd for $\text{C}_{30}\text{H}_{47}\text{O}_3$, 453.33632).

139 *Betulinic acid (3, purity percentage is 99.5%)*: White powder; ^1H NMR ($\text{C}_5\text{D}_5\text{N}$,
140 600 MHz) spectroscopic data: δ 0.84, 1.02, 1.07, 1.08, 1.23, 1.80 (3H each, all s, H₃-
141 24, 25, 26, 27, 23 and 29), 3.46 (1H, t like, *ca.* J = 8 Hz, H-3), 4.78, 4.95 (1H each,
142 both br. s, H₂-30); ^{13}C NMR ($\text{C}_5\text{D}_5\text{N}$, 150 MHz) spectroscopic data: see Tab. S1; ESI-
143 Q-Orbitrap MS *m/z* 455.35287 [M–H][–] (calcd for $\text{C}_{30}\text{H}_{47}\text{O}_3$, 455.35197); and
144 according to our identification, the chemical shift values of C-15 and C-21 in the
145 literature were exchanged.

146 *2 α -Hydroxybetulinic acid (4, purity percentage is 99.3%)*: White powder; ^1H
147 NMR ($\text{C}_5\text{D}_5\text{N}$, 500 MHz) spectroscopic data: δ 0.91, 1.05, 1.05, 1.06, 1.25, 1.79 (3H
148 each, all s, H₃-25, 24, 26, 27, 23 and 29), 3.38 (1H, d, J = 9.5 Hz, H-3), 4.08 (1H, dt, J
149 = 4.5, 9.5 Hz, H-2), 4.77, 4.93 (1H each, both br. s, H₂-30); ^{13}C NMR ($\text{C}_5\text{D}_5\text{N}$, 125
150 MHz) spectroscopic data: see Tab. S1; ESI-Q-Orbitrap MS *m/z* 471.34763 [M–H][–]
151 (calcd for $\text{C}_{30}\text{H}_{47}\text{O}_4$, 471.34689); and according to our identification, the chemical
152 shift values of C-23 and C-27, C-25 and C-26 in the literature were exchanged.

153 *3 β ,30-Dihydroxylup-20(29)-en-28-oic acid (5, purity percentage is 93.0%)*:

154 White powder; ^1H NMR (DMSO- d_6 , 500 MHz) spectroscopic data: δ 0.65, 0.76, 0.87,
155 0.93, 1.24 (3H each, all s, H₃-24, 25, 26, 27 and 23), 2.97 (1H, t like, *ca.* J = 8 Hz, H-
156 3), 3.89 (2H, s, H₂-29), 4.77, 4.86 (1H each, both br. s, H₂-30); ^{13}C NMR (DMSO- d_6 ,
157 125 MHz) spectroscopic data: see Tab. S1; ESI-Q-Orbitrap MS m/z 471.34747 [M-
158 H]⁻ (calcd for C₃₀H₄₇O₄, 471.34689).

159 *2-O-trans-p-Coumaroylalphitolic acid (6, purity percentage is 97.9%):* White
160 powder; ^1H NMR (C₅D₅N, 500 MHz) spectroscopic data: δ 1.01, 1.04, 1.09, 1.11,
161 1.30, 1.88 (3H each, all s, H₃-25, 26, 27, 24, 23 and 29), 3.66 (1H, d, J = 10.0 Hz, H-
162 3), 4.81, 4.96 (1H each, both br. s, H₂-29), 5.65 (1H, dt, J = 4.5, 10.0 Hz, H-2), 6.63,
163 8.03 (1H each, both d, J = 16.5 Hz, H-8',7'), 7.17 (2H, d, J = 8.5 Hz, H-3',5'), 7.51
164 (2H, d, J = 8.5 Hz, H-2',6'); ^{13}C NMR (C₅D₅N, 125 MHz) spectroscopic data: see Tab.
165 S1; ESI-Q-Orbitrap MS m/z 617.38452 [M-H]⁻ (calcd for C₃₉H₅₃O₆, 617.38367).

166 *3-O-cis-p-Coumaroylalphitolic acid (7, purity percentage is 97.3%):* White
167 powder; ^1H NMR (C₅D₅N, 600 MHz) spectroscopic data: δ [1.32 (1H, t, J = 10.8 Hz),
168 2.37 (1H, dd, J = 4.2, 10.8 Hz), H₂-1], 4.26 (1H, dt, J = 4.2, 10.8 Hz, H-2), 5.20 (1H,
169 d, J = 10.8 Hz, H-3), 1.03 (1H, m, overlapped, H-5), [1.35, 1.45 (1H, both m,
170 overlapped), H₂-6], [1.32 (1H, m), 1.35 (1H, m, overlapped), H₂-7], 1.45 (1H, m,
171 overlapped, H-9), 1.21, 1.50 (1H each, both m, H₂-11), 1.20, 1.92 (1H each, both m,
172 H₂-12), 2.72 (1H, dt, J = 3.0, 11.4 Hz, H-13), 1.22, 1.85 (1H each, both m, H₂-15),
173 [1.55 (1H, m), 2.63 (1H, dt, J = 3.0, 12.6 Hz), H₂-16], 1.74 (1H, t like, *ca.* J = 11 Hz,
174 H-18), 3.53 (1H, dt, J = 4.2, 10.8 Hz, H-19), 1.53, 2.23 (2H, m, H₂-21), 1.60, 2.25
175 (1H each, both m, H₂-22), 1.03, 0.96, 0.89, 1.03, 1.04, 1.78 (3H each, all s, H₃-23, 24,

176 25, 26, 27 and 29), 4.71, 4.94 (1H each, both br. s, H₂-30), 8.15 (2H, d, *J* = 8.5 Hz, H-
177 2',6'), 7.14 (2H, d, *J* = 8.5 Hz, H-3',5'), 6.93, 6.09 (1H each, both d, *J* = 12.6 Hz, H-
178 7', 8'); ¹³C NMR (C₅D₅N, 150 MHz) spectroscopic data: see Tab. S1; ESI-Q-Orbitrap
179 MS *m/z* 617.38422 [M-H]⁻ (calcd for C₃₉H₅₃O₆, 617.38367).

180 (*3α,4β,5β,8α,9β,10α,13α,14β,15β*)-13-Carboxy-4,9-dimethyl-15-(1-
181 methylethenyl)-3-(1-methylethyl)-18-norandrostane-4-propanoic acid (**8**, purity
182 percentage is 96.5%): White powder; ¹H NMR (C₅D₅N, 600 MHz) spectroscopic data:
183 δ 1.97 (2H, m, overlapped, H₂-1), 2.51 (2H, t, *J* = 7.8 Hz, H₂-2), 1.94 (1H, m, H-4),
184 1.18 (1H, m, overlapped, H-5), 1.33 (2H, m, H₂-6), 1.36, 1.42 (1H each, both m, H₂-
185 7), 1.72 (1H, br. d, *ca.* *J* = 12 Hz, H-9), 1.18, 1.54 (1H each, both m, overlapped, H₂-
186 11), 1.24, 1.94 (1H each, both m, H₂-13), 2.79 (1H, t like, *ca.* *J* = 11 Hz, H-14), 1.27,
187 1.84 (1H each, both m, H₂-15), 1.55, 2.63 (1H each, both m, H₂-16), 1.79 (1H, m,
188 overlapped, H-18), 3.55 (1H, t like, *ca.* *J* = 11 Hz, H-19), 1.53, 2.25 (2H, m, H₂-21),
189 1.57, 2.28 (1H each, both m, H₂-22), 0.94, 0.76, 0.79, 1.07, 1.12, 1.79 (3H each, all s,
190 H₃-23, 24, 25, 26, 27 and 29), 4.78, 4.96 (1H each, both s, H₂-30); ¹³C NMR (C₅D₅N,
191 150 MHz) spectroscopic data: see Tab. S1; ESI-Q-Orbitrap MS *m/z* 471.34756 [M-
192 H]⁻ (calcd for C₃₀H₄₇O₄, 471.34689).

193 *Ceanothic acid* (**9**, purity percentage is 99.0%): White powder; ¹H NMR (C₅D₅N,
194 500 MHz) spectroscopic data: δ 1.08, 1.16, 1.27, 1.40, 1.43, 1.67 (3H each, all s, H₃-
195 27, 26, 24, 25, 23 and 29), 4.67, 4.86 (1H each, both s, H₂-30); ¹³C NMR (C₅D₅N, 125
196 MHz) spectroscopic data: see Tab. S1; ESI-Q-Orbitrap MS *m/z* 485.32706 [M-H]⁻
197 (calcd for C₃₀H₄₅O₅, 485.32615). And according to our identification, the chemical

198 shift values of C-4 and C-8 in the literature were exchanged.

199 *Ceanothic acid 2-methyl ester (10, purity percentage is 98.2%):* White powder;
200 ^1H NMR ($\text{C}_5\text{D}_5\text{N}$, 600 MHz) spectroscopic data: δ 1.11, 1.14, 1.22, 1.31, 1.33, 1.78
201 (3H each, all s, H₃-26, 27, 24, 25, 23 and 29), 3.01 (1H, br. s, H-1), 4.60 (1H, br. s, H-
202 3), 4.74, 4.95 (1H each, both s, H₂-30); ^{13}C NMR ($\text{C}_5\text{D}_5\text{N}$, 150 MHz) spectroscopic
203 data: see Tab. S1; ESI-Q-Orbitrap MS *m/z* 499.34256 [M-H]⁻ (calcd for $\text{C}_{31}\text{H}_{47}\text{O}_5$,
204 499.3418).

205 *3-Oxo-oleana-12-en-28-oic acid (11, purity percentage is 96.3%):* White powder;
206 ^1H NMR ($\text{C}_5\text{D}_5\text{N}$, 500 MHz) spectroscopic data: δ 0.90, 0.97, 1.01, 1.02, 1.02, 1.16,
207 1.26 (3H each, all s, H₃-25, 29, 26, 24, 30, 23 and 27), 5.50 (1H, br. s, H-12); ^{13}C
208 NMR ($\text{C}_5\text{D}_5\text{N}$, 125 MHz) spectroscopic data: see Tab. S1; ESI-Q-Orbitrap MS *m/z*
209 453.33710 [M-H]⁻ (calcd for $\text{C}_{30}\text{H}_{45}\text{O}_3$, 453.33632). And according to our
210 identification, the chemical shift values of C-9 and C-17 in the literature were
211 exchanged.

212 *Oleanolic acid (12, purity percentage is 94.9%):* White powder; ^1H NMR
213 ($\text{C}_5\text{D}_5\text{N}$, 600 MHz) spectroscopic data: δ 0.91, 0.97, 1.03, 1.04, 1.04, 1.26, 1.30 (3H
214 each, all s, H₃-25, 29, 30, 24, 26, 23 and 27), 3.46 (1H, dd, *J* = 4.8, 10.2 Hz, H-3),
215 5.52 (1H, t, *J* = 3.6 Hz, H-12); ^{13}C NMR ($\text{C}_5\text{D}_5\text{N}$, 150 MHz) spectroscopic data: see
216 Tab. S2; ESI-Q-Orbitrap MS *m/z* 455.35303 [M-H]⁻ (calcd for $\text{C}_{30}\text{H}_{47}\text{O}_3$, 455.35197).

217 *Maslinic acid (13, purity percentage is 97.3%):* White powder; ^1H NMR ($\text{C}_5\text{D}_5\text{N}$,
218 500 MHz) spectroscopic data: δ 0.95, 0.99, 1.01, 1.01, 1.07, 1.27, 1.27 (3H each, all s,
219 H₃-29, 25, 26, 30, 24, 23 and 27), 3.38 (1H, d, *J* = 9.5 Hz, H-3), 4.07 (1H, ddd, *J* = 4.5,

220 10.0, 14.0 Hz, H-2), 5.46 (1H, t, J = 4.0 Hz, H-12); ^{13}C NMR (C₅D₅N, 125 MHz)
221 spectroscopic data: see Tab. S2; ESI-Q-Orbitrap MS m/z 471.34799 [M-H]⁻ (calcd
222 for C₃₀H₄₇O₄, 471.34689). And according to our identification, the chemical shift
223 values of C-1 and C-17 in the literature were exchanged.

224 *11-Oxo-maslinic acid (2 α ,3 β -dihydroxy-11-oxo-18 β -olean-12-en-28-oic acid (14,
225 purity percentage is 98.0%): White powder; ^1H NMR (CD₃OD, 600 MHz)
226 spectroscopic data: δ 0.81, 0.94, 0.96, 0.98, 1.02, 1.17, 1.41 (3H each, all s, H₃-24, 29,
227 30, 26, 23, 25 and 27), 2.92 (1H, d, J = 9.6 Hz, H-3), 3.67 (1H, ddd, J = 4.2, 9.6, 14.4
228 Hz, H-2), 5.56 (1H, s, H-12); ^{13}C NMR (CD₃OD, 150 MHz) spectroscopic data: see
229 Tab. S2; ESI-Q-Orbitrap MS m/z 485.32717 [M-H]⁻ (calcd for C₃₀H₄₅O₅, 485.32615).
230 And according to our identification, the chemical shift values of C-7 and C-22 in the
231 literature were exchanged.*

232 *2 α -trans-p-Coumaroyloxy-2 α ,3 β ,23 α -trihydroxy-olean-12-en-28-oic acid (15,
233 purity percentage is 91.5%): White powder; ^1H NMR (DMSO-*d*₆, 600 MHz)
234 spectroscopic data: δ 0.72, 0.77, 0.87, 0.87, 0.96, 0.99, 1.10 (3H each, all s, H₃-26, 24,
235 29, 30, 23, 25 and 27), 3.13 (1H, d, J = 10.8 Hz, H-3), 4.90 (1H, dt, *ca.* J = 4.8, 10.8
236 Hz, H-2), 5.17 (1H, br. s, H-12), 6.32, 7.54 (1H each, both d, J = 15.6 Hz, H-8',7'),
237 6.80 (2H, d, J = 8.4 Hz, H-3',5'), 7.52 (2H, d, J = 8.4 Hz, H-2',6'); ^{13}C NMR (DMSO-
238 *d*₆, 150 MHz) spectroscopic data: see Tab. S2; ESI-Q-Orbitrap MS m/z 617.38428
239 [M-H]⁻ (calcd for C₃₉H₅₃O₆, 617.38367).*

240 *2 α -cis-p-Coumaroyloxy-2 α ,3 β ,23 α -trihydroxy-olean-12-en-28-oic acid (16,
241 purity percentage is 98.0%): White powder; ^1H NMR (DMSO-*d*₆, 600 MHz)*

242 spectroscopic data: δ 0.72, 0.77, 0.87, 0.87, 0.98, 0.99, 1.10 (3H each, all s, H₃-26, 24,
243 29, 30, 23, 25 and 27), 3.13 (1H, d, J = 10.8 Hz, H-3), 4.90 (1H, dt, *ca.* J = 4.8, 10.8
244 Hz, H-2), 5.14 (1H, br. s, H-12), 5.75, 6.81 (1H each, both d, J = 13.2 Hz, H-8',7'),
245 6.75 (2H, d, J = 8.4 Hz, H-3',5'), 7.69 (2H, d, J = 8.4 Hz, H-2',6'); ¹³C NMR (DMSO-
246 d_6 , 150 MHz) spectroscopic data: see Tab. S2; ESI-Q-Orbitrap MS *m/z* 617.38440
247 [M-H]⁻ (calcd for C₃₉H₅₃O₆, 617.38367).

248 *3-O-trans-p-Coumaroyl maslinic acid (17, purity percentage is 98.0%)*: White
249 powder; ¹H NMR (C₅D₅N, 600 MHz) spectroscopic data: δ 0.97, 1.01, 1.01, 1.02,
250 1.04, 1.06, 1.28 (3H each, all s, H₃-29, 25, 26, 30, 24, 23 and 27), 4.29 (1H, ddd, J =
251 4.8, 10.2, 10.8 Hz, H-2), 5.24 (1H, d, J = 10.2 Hz, H-3), 5.47 (1H, br. s, H-12), 6.68,
252 8.00 (1H each, both d, J = 15.6 Hz, H-8',7'), 7.16 (2H, d, J = 8.4 Hz, H-3',5'), 7.56
253 (2H, d, J = 8.4 Hz, H-2',6'); ¹³C NMR (C₅D₅N, 150 MHz) spectroscopic data: see Tab.
254 S2; ESI-Q-Orbitrap MS *m/z* 617.38403 [M-H]⁻ (calcd for C₃₉H₅₃O₆, 617.38367).

255 *3,4-Seco-olean-12-ene-3,28-dioic acid (18, purity percentage is 98.3%)*: White
256 powder; ¹H NMR (C₅D₅N, 600 MHz) spectroscopic data: δ 0.77, 0.85, 0.95, 0.99,
257 1.02, 1.03, 1.26 (3H each, all s, H₃-24, 25, 23, 29, 30, 26 and 27), 5.49 (1H, br. s, H-
258 12); ¹³C NMR (C₅D₅N, 150 MHz) spectroscopic data: see Tab. S2; ESI-Q-Orbitrap
259 MS *m/z* 471.34741 [M-H]⁻ (calcd for C₃₀H₄₇O₄, 471.34689).

260 *3-Oxo-urs-12-en-28-oic acid (19, purity percentage is 96.5%)*: White powder;
261 ¹H NMR (C₅D₅N, 600 MHz) spectroscopic data: δ 0.89, 1.00, 1.02, 1.14, 1.20 (3H
262 each, all s, H₃-25, 24, 26, 23 and 27), 0.97 (3H, d, J = 6.0 Hz, H₃-30), 1.00 (1H, d, J =
263 6.0 Hz, H₃-29), 5.47 (1H, br. s, H-12); ¹³C NMR (C₅D₅N, 150 MHz) spectroscopic

264 data: see Tab. S2; ESI-Q-Orbitrap MS m/z 453.33716 [M–H][–] (calcd for C₃₀H₄₅O₃,
265 453.33632).

266 *Ursolic acid (20, purity percentage is 95.3%)*: White powder; ¹H NMR (C₅D₅N,
267 600 MHz) spectroscopic data: δ 0.91, 1.04, 1.07, 1.24, 1.26 (3H each, all s, H₃-25, 24,
268 26, 27 and 23), 0.97 (3H, d, J = 6.6 Hz, H₃-30), 1.02 (1H, d, J = 6.6 Hz, H₃-29), 3.47
269 (1H, dd, J = 5.4, 10.2 Hz, H-3), 5.51 (1H, t, J = 3.0 Hz, H-12); ¹³C NMR (C₅D₅N, 150
270 MHz) spectroscopic data: see Tab. S3; ESI-Q-Orbitrap MS m/z 455.35297 [M–H][–]
271 (calcd for C₃₀H₄₇O₃, 455.35197).

272 *2 α -Hydroxyursolic acid (21, purity percentage is 95.3%)*: White powder; ¹H
273 NMR (C₅D₅N, 500 MHz) spectroscopic data: δ 0.97, 1.03, 1.06, 1.21, 1.26 (3H each,
274 all s, H₃-25, 26, 24, 27 and 23), 0.96 (3H, d, J = 6.5 Hz, H₃-30), 0.99 (1H, d, J = 6.5
275 Hz, H₃-29), 3.38 (1H, d, J = 9.5 Hz, H-3), 4.07 (1H, ddd, J = 4.5, 9.5, 14.0 Hz, H-2),
276 5.47 (1H, t, J = 3.5 Hz, H-12); ¹³C NMR (C₅D₅N, 125 MHz) spectroscopic data: see
277 Tab. S3; ESI-Q-Orbitrap MS m/z 471.34784 [M–H][–] (calcd for C₃₀H₄₇O₄, 471.34689).

278 *Jacoumaric acid (22, purity percentage is 93.0%)*: White powder; ¹H NMR
279 (C₅D₅N, 500 MHz) spectroscopic data: δ 0.97 (3H, d, J = 6.0 Hz, H₃-30), 1.00 (3H, d,
280 J = 5.0 Hz, H₃-29), 1.01, 1.05, 1.05, 1.09, 1.24 (3H each, all s, H₃-25, 24, 26, 23 and
281 27), 4.29 (1H, dt, J = 5.0, 9.5 Hz, H-2), 5.27 (1H, d, J = 9.5 Hz, H-3), 5.48 (1H, t, J =
282 4.0 Hz, H-12), 6.68, 8.00 (1H each, both d, J = 16.0 Hz, H-8',7'), 7.17 (2H, d, J = 8.5
283 Hz, H-3',5'), 7.51 (2H, d, J = 8.5 Hz, H-2',6'); ¹³C NMR (C₅D₅N, 125 MHz)
284 spectroscopic data: see Tab. S3; ESI-Q-Orbitrap MS m/z 617.38409 [M–H][–] (calcd
285 for C₃₉H₅₃O₆, 617.38367). And according to our identification, the chemical shift

286 values of C-26 and C-29, C-3',5' and C-8' in the literature were exchanged.

287 *(1S,2S,4aR,4bS,6aS,9R,10S,10aS,12aR)-6a-Carboxy-*

288 *1,2,3,4,4a,4b,5,6,6a,7,8,9,10,10a,12,12a-hexadecahydro-1,4a,4b,9,10-pentamethyl-2-*

289 *(1-methylethyl)-1-chrysene propanoic acid (23, purity percentage is 92.8%): White*

290 powder; ^1H NMR ($\text{C}_5\text{D}_5\text{N}$, 600 MHz) spectroscopic data: δ 1.99 (2H, m, overlapped,

291 H₂-1), 2.53 (2H, t, J = 7.2 Hz, H₂-2), 1.92 (1H, m, H-4), 1.22 (1H, m, overlapped, H-

292 5), 1.35 (1H, m, H₂-6), 1.38, 1.46 (1H each, both m, H₂-7), 2.01 (1H, m, overlapped,

293 H-9), 1.95, 2.09 (1H each, both m, H₂-11), 5.48 (1H, t like, *ca.* J = 4 Hz, H-12), [1.23

294 (1H, m, overlapped), 2.31 (1H, br. t, *ca.* J = 11 Hz), H₂-15], 2.07, 2.12 (1H each, both

295 m, H₂-16), 2.64 (1H, d, J = 10.2 Hz, H-18), 1.45 (1H, m, H-19), 1.02 (1H, m, H-20),

296 2.00 (2H, m, overlapped, H₂-21), 1.37, 1.47 (1H each, both m, H₂-22), 0.93, 0.77,

297 0.85, 1.07, 1.24 (3H each, all s, H₃-23, 24, 25, 26 and 27), 0.94, 0.95 (3H each, both d,

298 J = 6.0 Hz, H₃-29 and 30); ^{13}C NMR ($\text{C}_5\text{D}_5\text{N}$, 150 MHz) spectroscopic data: see Tab.

299 S3; ESI-Q-Orbitrap MS m/z 471.34763 [M-H]⁻ (calcd for $\text{C}_{30}\text{H}_{47}\text{O}_4$, 471.34689).

300 *Pomonic acid (24, purity percentage is 93.3%): White powder; ^1H NMR ($\text{C}_5\text{D}_5\text{N}$,*

301 600 MHz) spectroscopic data: δ 0.93, 1.02, 1.10, 1.15, 1.71 (3H each, all s, H₃-25, 24,

302 26, 23 and 27), 1.14 (3H, d, J = 6.6 Hz, H₃-30), 5.61 (1H, br. s, H-12); ^{13}C NMR

303 ($\text{C}_5\text{D}_5\text{N}$, 150 MHz) spectroscopic data: see Tab. S3; ESI-Q-Orbitrap MS m/z

304 469.33218 [M-H]⁻ (calcd for $\text{C}_{30}\text{H}_{45}\text{O}_4$, 469.33124). And according to our

305 identification, the chemical shift values of C-23 and C-29 in the literature were

306 exchanged.

307 *Pomolic acid (25, purity percentage is 93.7%): White powder; ^1H NMR ($\text{C}_5\text{D}_5\text{N}$,*

308 600 MHz) spectroscopic data: δ 0.94, 1.05, 1.13, 1.26, 1.75 (3H each, all s, H₃-25, 24,
309 26, 23 and 27), 1.14 (3H, d, J = 6.0 Hz, H₃-30), 3.46 (1H, br. d, *ca.* J = 9 Hz, H-3),
310 5.63 (1H, br. s, H-12); ¹³C NMR (C₅D₅N, 150 MHz) spectroscopic data: see Tab. S3;
311 ESI-Q-Orbitrap MS *m/z* 471.34744 [M-H]⁻ (calcd for C₃₀H₄₇O₄, 471.34689).


312 *2-Oxopomolic acid (26, purity percentage is 93.3%)*: White powder; ¹H NMR
313 (C₅D₅N, 600 MHz) spectroscopic data: δ 0.88, 0.89, 1.06, 1.33, 1.76 (3H each, all s,
314 H₃-24, 26, 25, 23 and 27), 1.14 (3H, d, J = 6.6 Hz, H₃-30), 1.44 (3H, s, H₃-29), 4.20
315 (1H, s, H-3), 5.58 (1H, t, J = 3.6 Hz, H-12); ¹³C NMR (C₅D₅N, 150 MHz)
316 spectroscopic data: see Tab. S3; ESI-Q-Orbitrap MS *m/z* 485.32736 [M-H]⁻ (calcd
317 for C₃₀H₄₅O₅, 485.32615). And the chemical shift value of C-11 in the literature was
318 revised here.

319 *Euscaphic acid (27, purity percentage is 98.3%)*: White powder; ¹H NMR
320 (C₅D₅N, 500 MHz) spectroscopic data: δ 0.92, 0.99, 1.12, 1.29, 1.66 (3H each, all s,
321 H₃-24, 25, 26, 23 and 27), 1.13 (3H, d, J = 6.5 Hz, H₃-30), 3.79 (1H, d, J = 2.5 Hz, H-
322 3), 4.33 (1H, dt, J = 2.5, 11.0 Hz, H-2), 5.60 (1H, br. s, H-12); ¹³C NMR (C₅D₅N, 125
323 MHz) spectroscopic data: see Tab. S3; ESI-Q-Orbitrap MS *m/z* 487.34286 [M-H]⁻
324 (calcd for C₃₀H₄₇O₅, 487.34180).

325 *2 β ,19 α -Hydroxyursolic acid (28, purity percentage is 97.0%)*: White powder; ¹H
326 NMR (C₅D₅N, 500 MHz) spectroscopic data: δ 1.15 (3H, d, J = 6.5 Hz, H₃-30), 1.19,
327 1.29, 1.41, 1.56, 1.79 (3H each, all s, H₃-26, 23, 24, 25 and 27), 1.49 (3H, s, H₃-29),
328 3.45 (1H, d, J = 3.0 Hz, H-3), 4.44 (1H, q, J = 3.0 Hz, H-2), 5.63 (1H, br. d, *ca.* J = 4
329 Hz, H-12); ¹³C NMR (C₅D₅N, 125 MHz) spectroscopic data: see Tab. S3; ESI-Q-

330 Orbitrap MS m/z 487.34277 [M-H]⁻ (calcd for C₃₀H₄₇O₅, 487.34180). And the
331 chemical shift value of C-2 in the literature was revised here.


332 *Cecropiacic acid (29, purity percentage is 99.0%):* White powder; ¹H NMR
333 (C₅D₅N, 600 MHz) spectroscopic data: δ 1.09 (3H, d, J = 6.6 Hz, H₃-30), 1.19, 1.20,
334 1.36, 1.56, 1.59, 1.88 (3H each, all s, H₃-26, 25, 29, 23, 24 and 27), 5.66 (1H, t like,
335 *ca.* J = 4 Hz, H-12); ¹³C NMR (C₅D₅N, 150 MHz) spectroscopic data: see Tab. S3;
336 ESI-Q-Orbitrap MS m/z 517.31659 [M-H]⁻ (calcd for C₃₀H₄₅O₇, 517.31598).
337 According to our identification, the chemical shift values of H₃-23 and H₃-24 in the
338 literature were exchanged.



341

342
343**Fig. S1.** ^1H NMR (600MHz, CD_3OD) spectrum of compound 1

344

345
346**Fig. S2.** ^{13}C NMR (150MHz, CD_3OD) spectrum of compound 1




Fig. S3. The ^1H ^1H COSY (CD_3OD) spectrum of compound **1**






Fig. S4. The HSQC (CD_3OD) spectrum of compound 1




353
354
355

Fig. S5. The HMBC (CD_3OD) spectrum of compound 1



356
357
358



Fig. S6. The NOESY (CD_3OD) spectrum of compound 1




359

360

Fig. S7. The ESI-Q-Orbitrap MS spectrum of compound 1



**Fig. S8.** ^1H NMR (500MHz, CDCl_3) spectrum of compound 2**Fig. S9.** ^{13}C NMR (125MHz, CDCl_3) spectrum of compound 2




369

370

Fig. S10. The ESI-Q-Orbitrap MS spectrum of compound 2


**Fig. S11.** ^1H NMR (600MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 3**Fig. S12.** ^{13}C NMR (150MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 3



379

380

Fig. S13. The ESI-Q-Orbitrap MS spectrum of compound **3**



382
383
384

Fig. S14. ^1H NMR (500MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 4






Fig. S15. ^{13}C NMR (125MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 4




388
389
390

Fig. S16. The ESI-Q-Orbitrap MS spectrum of compound 4



393 **Fig. S17.** ^1H NMR (500MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound **5**
 394



396 **Fig. S18.** ^{13}C NMR (125MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound **5**
 397
 398





Fig. S19. The ESI-Q-Orbitrap MS spectrum of compound 5


399
400
401



403

404

405


Fig. S20. ^1H NMR (500MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound **6**

406

407

408



Fig. S21. ^{13}C NMR (125MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound **6**




409

410

Fig. S22. The ESI-Q-Orbitrap MS spectrum of compound 6





418

419

Fig. S25. The ESI-Q-Orbitrap MS spectrum of compound 7




Fig. S26. ^1H NMR (600MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound **8**







Fig. S27. ^{13}C NMR (150MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound **8**




428

429



Fig. S28. The ESI-Q-Orbitrap MS spectrum of compound **8**






437
438
439

Fig. S31. The ESI-Q-Orbitrap MS spectrum of compound 9






447

Fig. S34. ^{13}C NMR (150MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum-2 of compound **10**



449




450

Fig. S35. The ESI-Q-Orbitrap MS spectrum of compound **10**

451






460


461

Fig. S38. The ESI-Q-Orbitrap MS spectrum of compound 11

462




464

465
466**Fig. S39.** ^1H NMR (600MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound **12**


467

468
469**Fig. S40.** ^{13}C NMR (150MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum-1 of compound **12**




470
471
472

Fig. S41. ^{13}C NMR (150MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum-2 of compound **12**



473
474
475

Fig. S42. The ESI-Q-Orbitrap MS spectrum of compound **12**




477

Fig. S43. ^1H NMR (500MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound **13**

478

479



480

Fig. S44. ^{13}C NMR (125MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound **13**

481

482




Fig. S45. The ESI-Q-Orbitrap MS spectrum of compound 13

483

484

485




Fig. S46. ^1H NMR (600MHz, CD₃OD) spectrum of compound **14**





Fig. S47. ^{13}C NMR (150MHz, CD_3OD) spectrum of compound **14**






493

494

Fig. S48. The ESI-Q-Orbitrap MS spectrum of compound 14

495







503

504

Fig. S51. The ESI-Q-Orbitrap MS spectrum of compound **15**

**Fig. S52.** ^1H NMR (600MHz, DMSO- d_6) spectrum of compound 16**Fig. S53.** ^{13}C NMR (150MHz, DMSO- d_6) spectrum of compound 16







Fig. S54. The ESI-Q-Orbitrap MS spectrum of compound 16

513
514
515

**Fig. S55.** ^1H NMR (600MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 17**Fig. S56.** ^{13}C NMR (150MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 17



524

525

526

Fig. S57. The ESI-Q-Orbitrap MS spectrum of compound 17




Fig. S58. ^1H NMR (600MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound **18**

528

529









Fig. S59. ^{13}C NMR (150MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum-1 of compound **18**

532

533










546

547

548

Fig. S64. The ESI-Q-Orbitrap MS spectrum of compound **19**






556

557

558

Fig. S67. The ESI-Q-Orbitrap MS spectrum of compound **20**








Fig. S70. The ESI-Q-Orbitrap MS spectrum of compound 21

566

567

568








Fig. S73. The ESI-Q-Orbitrap MS spectrum of compound **22**







580


581
582**Fig. S74.** ^1H NMR (600MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 23

583

584
585**Fig. S75.** ^{13}C NMR (150MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum-1 of compound 23









598

599


Fig. S80. The ESI-Q-Orbitrap MS spectrum of compound 24



601 Fig. S81. ^1H NMR (600MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 25
602
603





604 Fig. S82. ^{13}C NMR (150MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound 25
605
606






607

608

Fig. S83. The ESI-Q-Orbitrap MS spectrum of compound **25**








623

624

625

Fig. S88. ^1H NMR (500MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound **27**

626

627

628

Fig. S89. ^{13}C NMR (125MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum of compound **27**







Fig. S90. The ESI-Q-Orbitrap MS spectrum of compound 27



629
630
631






639
640
641

Fig. S93. The ESI-Q-Orbitrap MS spectrum of compound **28**






649

650


651

Fig. S96. ^{13}C NMR (150MHz, $\text{C}_5\text{D}_5\text{N}$) spectrum-2 of compound **29**


652

653


Fig. S97. The ESI-Q-Orbitrap MS spectrum of compound **29**




655



656




657



658

659

Fig. S98. The MTT assay compounds 1-29 at 1, 5, 10, 25 and 50 μ M660 N: normal group without tested samples. Values represent the mean \pm SD of six determinations.661 ** $P < 0.01$, *** $P < 0.001$ (Differences between compound-treated group and normal group). n = 6.



663

664

Fig. S99. The raw data of Fig. 3

Tab. S1. ^{13}C -NMR data for **2–11**

No.	2^a	3^b	4^b	5^c	6^b	7^b	8^b	9^b	10^b	11^b
1	39.6	39.5	48.2	38.2	45.0	48.9	34.2	67.0	66.3	39.1
2	34.2	28.3	68.8	27.1	73.8	66.5	29.8	178.1	175.9	34.4
3	218.1	78.1	83.7	76.7	79.9	84.9	177.3	84.7	84.6	216.0
4	47.4	39.4	39.9	38.4	40.5	39.7	25.7	43.5	43.4	47.4
5	55.0	55.9	56.0	54.8	55.8	55.6	47.4	57.0	57.2	55.4
6	19.7	18.8	18.8	17.9	18.8	18.6	18.6	19.1	19.0	19.8
7	33.7	34.8	34.8	33.9	32.9	34.6	33.4	34.7	34.5	32.6
8	40.7	41.1	41.2	42.2	41.1	41.1	40.8	43.9	43.8	39.6
9	49.9	51.0	51.0	49.9	50.9	50.8	41.2	45.1	45.0	47.2
10	37.1	37.5	38.7	38.4	38.8	38.6	40.2	49.7	49.7	36.9
11	21.4	21.2	21.3	20.5	21.3	21.3	22.0	24.2	24.0	23.8
12	25.6	26.1	26.0	26.1	26.1	26.0	26.1	26.3	26.1	122.3
13	38.5	38.6	38.6	37.4	38.6	38.5	38.7	39.1	39.0	144.9
14	42.5	42.8	42.9	40.2	42.9	42.9	43.3	42.1	42.1	42.2
15	29.8	30.3	30.2	29.2	30.2	30.2	30.3	30.5	30.5	28.3
16	32.3	32.9	32.9	31.7	32.9	32.8	32.9	33.0	32.9	23.7
17	56.4	56.6	56.6	55.4	56.6	56.6	56.8	56.6	56.7	46.7
18	49.3	49.8	49.8	48.8	49.8	49.7	49.7	49.7	49.7	42.1
19	46.9	47.8	47.8	41.9	47.8	47.8	47.8	47.6	47.7	46.4
20	150.6	151.3	151.3	155.5	151.4	151.3	151.5	151.2	151.2	31.0
21	30.7	31.2	31.2	28.6	31.2	31.2	31.3	31.3	31.3	34.2
22	37.0	37.6	37.6	36.2	37.7	37.6	37.6	37.6	37.6	33.2
23	26.7	28.7	29.2	28.0	29.1	28.9	24.9	31.5	31.5	26.6
24	21.0	16.4	17.4	15.7	16.3	18.0	19.1	20.4	20.2	21.6
25	15.9	16.4	17.7	15.9	17.4	17.6	20.0	18.8	18.6	14.9
26	16.0	16.4	16.5	15.9	17.4	16.4	16.4	17.0	17.0	17.2
27	14.6	14.9	14.9	14.3	14.9	14.9	14.8	15.1	15.0	26.0
28	180.3	179.0	179.1	177.2	179.0	179.0	179.4	178.9	179.0	180.2
29	19.4	19.5	19.5	62.8	19.4	19.4	19.5	19.6	19.5	33.3
30	109.6	110.0	109.9	105.3	110.0	110.0	110.0	109.8	109.9	23.7
2-OCH ₃										51.1
1'					126.2	126.7				
2'					130.6	133.8				
3'					116.9	115.9				
4'					161.4	160.5				
5'					116.9	115.9				
6'					130.6	133.8				
7'					144.7	143.6				
8'					116.0	117.1				
9'					167.5	167.2				

Tab. S2. ^{13}C -NMR data for **12–20**

No.	12 ^b	13 ^b	14 ^d	15 ^c	16 ^c	17 ^b	18 ^b	19 ^b	20 ^b
1	39.0	47.7	48.5	43.4	43.4	48.3	34.1	39.3	39.1
2	28.1	68.6	69.2	71.8	71.8	66.4	29.8	34.3	28.1
3	78.1	83.8	84.2	78.2	78.2	85.0	177.3	216.1	78.1
4	39.4	39.8	40.6	40.7	40.9	39.8	25.3	47.1	39.4
5	55.8	55.9	56.2	54.2	54.2	55.5	47.9	55.3	55.8
6	18.8	18.8	18.7	18.0	18.0	18.7	18.5	19.8	18.8
7	33.2	33.2	34.0	32.1	32.1	33.0	32.2	32.9	33.6
8	39.8	39.8	45.1	39.2	38.8	39.8	39.6	39.8	40.0
9	48.2	48.1	63.0	46.7	46.7	48.0	38.4	47.3	48.1
10	37.4	38.5	39.4	37.7	37.7	38.4	40.2	36.8	37.5
11	23.9	23.9	202.7	23.2	23.2	23.9	24.1	23.7	23.7
12	122.6	122.4	128.3	121.2	121.2	122.3	122.7	125.4	125.7
13	144.9	144.8	173.1	143.9	143.9	145.0	144.8	139.3	140.1
14	42.2	42.2	46.5	41.3	41.3	42.2	42.7	42.5	42.5
15	28.4	28.3	28.9	27.1	27.1	28.3	28.4	28.6	28.7
16	23.7	23.7	24.0	22.8	22.8	23.7	23.8	24.9	24.9
17	46.7	46.6	47.3	45.6	45.6	46.7	46.8	48.1	48.1
18	42.1	42.0	43.5	41.3	40.9	42.0	42.1	53.6	53.6
19	46.5	46.5	45.7	45.3	45.3	46.5	46.5	39.5	39.5
20	31.0	30.9	31.7	30.3	30.0	31.0	31.0	39.4	39.4
21	34.3	34.2	34.8	33.2	33.2	34.3	34.3	31.1	31.1
22	33.2	33.2	33.0	32.0	32.1	33.2	33.2	37.4	37.3
23	28.8	29.3	29.3	28.5	28.4	29.0	24.9	26.7	28.8
24	16.6	17.6	17.5	16.9	16.7	18.3	19.1	21.6	16.6
25	15.6	16.8	18.0	16.0	16.0	16.8	19.5	15.1	15.7
26	17.5	17.5	19.9	16.7	16.9	17.4	17.6	17.3	17.5
27	26.2	26.2	24.0	25.5	25.5	26.2	26.0	23.7	23.9
28	180.3	180.2	181.4	178.7	179.7	180.5	180.5	179.8	180.0
29	33.3	33.3	33.3	32.7	32.7	33.3	33.3	17.5	17.6
30	23.8	23.8	23.8	23.3	23.3	23.8	23.8	21.4	21.4
1'				125.1	125.8	126.2			
2'				130.0	132.5	130.6			
3'				115.7	114.7	116.8			
4'				159.6	159.2	161.4			
5'				115.7	114.7	116.8			
6'				130.0	132.5	130.6			
7'				144.0	142.3	144.8			
8'				114.9	116.2	116.0			
9'				166.3	166.3	167.9			

^a CDCl₃; ^b C₅D₅N; ^c DMSO-*d*₆; ^d CD₃OD

Tab. S3. ^{13}C -NMR data for **21–29**

No.	21^b	22^b	23^b	24^b	25^b	26^b	27^b	28^b	29^b
1	47.9	48.6	34.3	39.2	39.0	53.7	42.9	45.0	42.4
2	68.6	66.4	29.9	34.4	28.2	211.2	66.1	71.5	174.5
3	83.8	85.1	177.3	216.5	78.2	83.5	79.4	78.5	182.4
4	39.8	39.8	25.4	47.5	39.4	45.8	38.8	38.8	46.9
5	55.9	55.6	47.9	55.5	55.9	54.9	48.8	56.1	48.9
6	18.8	18.7	18.6	19.9	19.0	19.2	18.6	18.8	22.1
7	33.5	33.4	31.2	33.0	33.7	33.2	33.5	33.7	33.0
8	40.0	40.0	39.8	40.2	40.4	42.3	40.6	40.5	40.5
9	48.1	48.0	38.2	46.9	47.8	47.4	47.6	48.2	39.5
10	38.4	38.3	40.1	36.9	37.4	40.7	38.7	37.3	48.4
11	23.9	23.7	24.1	24.0	24.1	23.9	24.1	24.2	24.5
12	125.5	125.4	125.8	127.8	128.0	127.4	127.9	128.2	128.5
13	139.3	139.6	139.3	140.0	140.1	140.2	140.0	140.0	139.7
14	42.5	42.6	43.1	42.2	42.2	43.7	42.2	42.3	42.7
15	28.6	28.7	28.7	29.3	29.4	29.5	29.3	29.3	29.4
16	24.9	24.9	25.0	26.4	26.5	26.4	26.4	26.4	26.6
17	48.0	48.1	48.1	48.3	48.4	48.3	48.3	48.3	48.4
18	53.5	53.6	53.7	54.7	54.7	54.6	54.6	54.7	54.7
19	39.5	39.5	39.6	72.7	72.7	72.7	72.7	72.7	72.7
20	39.4	39.4	39.4	42.4	42.4	42.4	42.4	42.4	42.3
21	31.1	31.1	32.5	26.9	27.0	27.0	27.0	27.0	26.9
22	37.4	37.5	37.5	38.5	38.6	38.5	38.6	38.6	38.5
23	29.4	29.0	24.9	26.6	28.8	29.3	29.5	30.3	27.6
24	17.7	18.3	19.7	21.6	16.6	16.8	22.3	18.2	25.0
25	17.0	16.8	19.7	15.0	15.6	16.4	16.7	16.7	19.6
26	17.5	17.4	17.7	17.0	17.3	17.3	17.3	17.3	17.3
27	23.7	24.0	23.8	24.5	24.7	24.6	24.6	24.8	24.3
28	179.9	180.3	180.2	180.8	180.9	180.7	181.1	180.8	180.9
29	17.5	17.5	17.7	27.1	27.2	27.1	27.1	27.1	27.2
30	21.4	21.4	21.4	16.8	16.8	16.8	16.8	16.8	16.7
1'		126.3							
2'		130.6							
3'		116.8							
4'		161.4							
5'		116.8							
6'		130.6							
7'		144.8							
8'		116.1							
9'		167.9							

^a CDCl₃; ^b C₅D₅N; ^c DMSO-d₆; ^d CD₃OD

677

678
679**Tab. S4.** Comparison ^1H and ^{13}C NMR chemical shifts of maslinic acid, augustic acid,
bredemolic acid and 3-*epi*-maslinic acid

	Maslinic acid (2 α 3 β)	3- <i>epi</i> -Maslinic acid (2 α 3 α)	Bredemolic acid (2 β 3 α)	Augustic acid (2 β 3 β)
$\delta_{\text{H-2}}$	4.11	4.21	4.36	4.41
$\delta_{\text{H-3}}$	3.41	3.77	4.00	3.44
$\Delta\delta_{\text{H2-H3}}$	0.7	0.56	0.36	0.97
$J_{\text{H2,3}}$	9.4	2.6	7.5	4.0
$\delta_{\text{C-2}}$	69.0	66.5	71.1	71.8
$\delta_{\text{C-3}}$	84.3	79.7	78.7	78.7
$\Delta\delta_{\text{C3-C2}}$	15.3	13.2	7.6	6.9

680